(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €38.70 | 2.79% | 8.13% |
| CEGEDIM (CGM.PA) | €19.16 | 2.56% | 5.08% |
| TUBIZE-FIN (TUB.BR) | €75.90 | 1.13% | 4.93% |
| SARTORIUS STED BIO (DIM.PA) | €239.20 | 0.56% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
2.79% Forward Dividend Yield and 8.13% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.87.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 13.48. Meaning, the purchaser of the share is investing €13.48 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
Volatility
BOIRON’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.32%, a negative 0.19%, and a positive 1.13%.
BOIRON’s highest amplitude of average volatility was 0.32% (last week), 1.00% (last month), and 1.13% (last quarter).
Volume
Today’s last reported volume for BOIRON is 1901 which is 65.58% below its average volume of 5523.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BOIRON’s stock is considered to be overbought (>=80).
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.6%, now sitting on 534.24M for the twelve trailing months.
More news about BOIRON.
2. CEGEDIM (CGM.PA)
2.56% Forward Dividend Yield and 5.08% Return On Equity
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 19.16. Meaning, the purchaser of the share is investing €19.16 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 555.21M for the twelve trailing months.
More news about CEGEDIM.
3. TUBIZE-FIN (TUB.BR)
1.13% Forward Dividend Yield and 4.93% Return On Equity
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.88.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 40.37. Meaning, the purchaser of the share is investing €40.37 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Moving Average
TUBIZE-FIN’s value is below its 50-day moving average of €76.58 and higher than its 200-day moving average of €72.34.
More news about TUBIZE-FIN.
4. SARTORIUS STED BIO (DIM.PA)
0.56% Forward Dividend Yield and 32.37% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €9.58.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 24.97. Meaning, the purchaser of the share is investing €24.97 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Volatility
SARTORIUS STED BIO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.19%, a negative 0.86%, and a positive 1.79%.
SARTORIUS STED BIO’s highest amplitude of average volatility was 0.93% (last week), 2.22% (last month), and 1.79% (last quarter).
Sales Growth
SARTORIUS STED BIO’s sales growth is negative 15.8% for the present quarter and negative 10.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.8%, now sitting on 3.36B for the twelve trailing months.
More news about SARTORIUS STED BIO.
